3 Biotech Stocks With Great Potential in 2014
moreView todays social media effects on VRTXView the latest stocks trending across Twitter. Click to view dashboardSee who Vertex is hiring next, click here to view […]
moreView todays social media effects on VRTXView the latest stocks trending across Twitter. Click to view dashboardSee who Vertex is hiring next, click here to view […]
[ACN Newswire] – Medgenics’ (NYSEAMEX: MDGN) INFRADURE(TM) provides sustained production and delivery of interferon-alpha for the treatment of hepatitis. INFRADURE(TM) is a kind of miniature pump that is impacted into … moreView todays social media effects on VRTXView the latest stocks trending across Twitter. Click to view dashboardSee who Vertex is hiring next, click here to view […]
[ACN Newswire] – By Ivan DeryuginThe biotechnology sector is one where growth is, for the most part, fueled by a single factor: new drugs. Companies that develop the next generation of drugs for a market stand to gain … moreView todays social media effects on VRTXView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Jake KingWith Gilead’s (NASDAQ:GILD) reported 100% Hepatitis C virologic response rate over the weekend, rivals Achillion (NASDAQ:ACHN) and Vertex (NASDAQ:VRTX) traded down 15% and 5% respectively at … moreView todays social media effects on VRTXView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Jake KingHepatitis C drug developers have been swiftly moving towards interferon-free, oral regimens, and while Vertex’s (NASDAQ:VRTX) Incivek was briefly the lead treatment in the field, it may soon … moreView todays social media effects on VRTXView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By David SobekIn November of 2011, Gilead (NASDAQ:GILD) announced that it reached an agreement to purchase Pharmasset for $11 billion, an 89% premium to its previous close. CEO John Martin noted , the … moreView todays social media effects on VRTXView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Jake KingDevelopers of potential Hepatitis C (HCV) treatments are among the most-traded in the healthcare industry on Monday, following an announcement from Abbot Laboratories (NYSE:ABT) that a combinations … moreView todays social media effects on VRTXView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Jake KingOn Tuesday, Vertex Pharmaceuticals (NASDAQ:VRTX) announced that while it would be advancing its developmental Hepatitis C (HCV) treatment, ALS-2200, into Phase II testing, ALS-2158 didn’t make … moreView todays social media effects on VRTXView the latest stocks trending across Twitter. Click to view dashboard […]